Edgewise: breaking away from dystrophin for muscular dystrophy
Edgewise emerges from stealth with $50M series B, dystrophin-independent muscle-stabilizing compounds
With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy.
Edgewise Therapeutics emerged from stealth this month with a $50 million series B round co-led by Novo Holdings A/S and U.S. Venture Partners and a portfolio of internally developed small molecule therapies for musculoskeletal indications including Duchenne and Becker muscular dystrophy.
Cure Duchenne Ventures, Deerfield Management, New Leaf Venture Partners and founding investor OrbiMed Advisors